Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. (Nasdaq: INBX) is a clinical-stage biopharmaceutical company that focuses on developing a broad pipeline of novel biologic therapeutic candidates targeting oncology and rare diseases. With its proprietary modular protein engineering platforms, Inhibrx aims to create therapeutic candidates that address complex disease biology effectively. The company’s leading candidates include INBRX-109 and INBRX-106, which utilize multivalent formats to optimize agonist functions for specific targets.
One of the notable projects is INBRX-101, a recombinant human AAT-Fc fusion protein designed to treat patients with Alpha-1 Antitrypsin Deficiency (AATD). The ElevAATe trial, a randomized, controlled, double-blind, head-to-head superiority study, is currently evaluating INBRX-101 against plasma-derived AAT therapies. The trial aims to achieve sustained therapeutic levels with a less frequent dosing interval, addressing the limitations of current weekly infusions required by existing treatments. Initial results are anticipated by late 2024.
In another strategic move, Inhibrx has secured global rights for INBRX-101, as Chiesi Farmaceutici S.p.A declined the option for ex-North American rights, promising broader strategic opportunities in launching treatments for conditions like Graft versus Host Disease (GvHD) in markets such as Europe and Japan.
Additionally, the company has shown promising results in their Phase 1 trial of INBRX-109 combined with chemotherapies for advanced Ewing sarcoma, indicating a disease control rate of 76.9% among evaluated patients, with the majority achieving partial responses or stable disease.
Financially, Inhibrx is on the verge of a significant transaction with Sanofi, which involves the sale of INBRX-101 assets while spinning off its remaining pipeline into a new publicly traded entity, Inhibrx Biosciences, Inc. This move will position Inhibrx to continue advancing its other clinical programs and leverage its strong pipeline for future developments.
For more detailed information, visit their official website at www.inhibrx.com.
Inhibrx, Inc. (Nasdaq: INBX) announced the initiation of a registration-enabling trial for INBRX-101, a recombinant human AAT-Fc fusion protein targeting emphysema due to alpha-1 antitrypsin deficiency. This trial, named ElevAATe, includes 36 patients receiving doses every three weeks and aims to measure functional AAT concentration over 32 weeks across 35 sites in the U.S., Australia, and New Zealand. Additionally, the FDA lifted the partial clinical hold on INBRX-109, a DR5 agonist. Patient enrollment for INBRX-109 will resume next month, with data anticipated by late 2023 for Phase 1 cohorts and late 2024 for the registration trial data. The company continues to advance its clinical pipeline in oncology and rare diseases.
Inhibrx, Inc. (NASDAQ: INBX) reported its financial results for Q4 and fiscal year 2022, showing significant increases in cash and cash equivalents, totaling $273.9 million, up from $131.3 million in 2021. R&D expenses rose to $30.5 million in Q4, compared to $18.6 million in the previous year, and net loss widened to $40.9 million or $0.95 per share. Key clinical updates include the initiation of INBRX-101's trial for Alpha-1 Antitrypsin Deficiency expected in April 2023 and promising results from INBRX-105. Despite increased operational costs, the company remains focused on advancing its clinical pipeline.
Inhibrx, Inc. (NASDAQ: INBX) and NorthStar Medical Radioisotopes have announced a collaboration to develop innovative radiopharmaceuticals targeting cancer treatment. This partnership leverages Inhibrx's optimized single-domain antibodies for targeted alpha therapies and NorthStar’s capacity as a supplier of non-carrier added actinium-225 (Ac-225) and copper-67 (Cu-67). The collaboration aims to enhance the efficacy of targeted therapies while ensuring sufficient supply for clinical and commercial use.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the 5th Annual HealthCONx Conference on November 30 at 8:45 a.m. PT. This virtual investor conference will include a live webcast of the presentation, available for at least 60 days on Inhibrx's investor website.
As a clinical-stage biopharmaceutical company, Inhibrx focuses on therapeutics for oncology and rare diseases, employing innovative protein engineering techniques. To learn more, visit www.inhibrx.com.
Inhibrx, Inc. (Nasdaq: INBX) reported updated efficacy and safety results from its Phase 1 trial of INBRX-109 for treating chondrosarcoma. Among 33 evaluable patients, the disease control rate was 87.9%, with 14 patients showing clinical benefits lasting over 6 months. The treatment exhibited a median progression-free survival of 7.6 months, with minimal adverse events. INBRX-109 has received Fast Track and orphan drug designations from FDA, highlighting its significance in treating this rare cancer.
FAQ
What is the current stock price of Inhibrx Biosciences (INBX)?
What is the market cap of Inhibrx Biosciences (INBX)?
What is Inhibrx Biosciences, Inc.?
What are the main therapeutic candidates of Inhibrx?
What is INBRX-101?
What is the ElevAATe trial?
What were the results of the Phase 1 trial for INBRX-109?
What is the significance of Chiesi declining the option for INBRX-101?
What is the financial condition of Inhibrx?
What is the significance of the acquisition by Sanofi?
Will Inhibrx continue as a publicly traded company?
Where can I find more information about Inhibrx?
